New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 17, 2014
10:00 EDTEWEdwards Lifesciences rises 5.9%
Edwards Lifesciences is up 5.9%, or $4.66, to $83.10
News For EW From The Last 14 Days
Check below for free stories on EW the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 16, 2014
07:27 EDTEWEdwards Lifesciences price target raised to $114 from $103 at Canaccord
Canaccord raised its price target on Edwards Lifesciences to $114 from $103 following positive updates on the SAPIEM franchise and on the heels of several positive trends and upside surprises across the businesses during the quarter. Canaccord maintains its Buy rating on the stock.
September 15, 2014
07:45 EDTEWCardiovascular Research Foundation to hold a conference
Transcatheter Cardiovascular Therapeutics: TCT 2014 to be held in Washington, D.C. on September 13-17 with some presentations being webcasted. Webcast Link
September 14, 2014
13:18 EDTEWEdwards Lifesciences presents five-year clinical outcomes of PARTNER trial
Edwards Lifesciences announced the presentation of five-year clinical outcomes for inoperable patients treated in The PARTNER Trial, the world's only prospective randomized trial for transcatheter aortic valve replacement, TAVR, in patients deemed too sick for open-heart surgery. The data were presented as part of the late-breaking clinical trials session at the 26th Transcatheter Cardiovascular Therapeutics, TCT, the annual scientific symposium of the Cardiovascular Research Foundation."These longer term results from PARTNER's inoperable cohort indicated that TAVR was associated with a continued significant mortality benefit, persistent symptom benefit and a statistically significant reduction in rehospitalizations," said Michael J. Mack, M.D., chair, cardiovascular service line, Baylor Scott & White Health. "It is reassuring now five years later that in this very ill and elderly patient group facing a high likelihood of mortality, more patients treated with SAPIEN experienced sustained improvements in functional heart status and fewer repeat hospitalizations two measures that signify an improvement in quality of life." "This was the first study of its kind for transcatheter heart valves," said Mack. "The PARTNER Trial has historical significance in the development of TAVR and continues to provide the clinical community with important information about the durability and performance of the Edwards SAPIEN valves."
September 12, 2014
15:03 EDTEWSt. Jude Medical pausing Portico sales, implants, says Wells Fargo
Subscribe for More Information
September 11, 2014
10:00 EDTEWOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Airgas (ARG) initiated with a Neutral at Northcoast... CBOE Holdings (CBOE) initiated with a Buy at Deutsche Bank... CME Group (CME) initiated with a Buy at Deutsche Bank... Colfax (CFX) initiated with a Neutral at Northcoast... Corporate Office Properties (OFC) initiated with an Overweight at Capital One... Edwards Lifesciences (EW) initiated with a Buy at Sterne Agee... Energen (EGN) initiated with a Buy at Deutsche Bank... Goodrich Petroleum (GDP) initiated with an Outperform at Cowen... GreenHunter Resources (GRH) initiated with a Hold at Stifel... GrubHub (GRUB) initiated with a Market Perform at Barrington... Illinois Tool Works (ITW) initiated with a Neutral at Northcoast... IntercontinentalExchange (ICE) initiated with a Hold at Deutsche Bank... JD.com (JD) initiated with a Buy at Brean Capital... Lincoln Electric (LECO) initiated with a Buy at Northcoast... Live Nation (LYV) initiated with a Buy at Jefferies... Medtronic (MDT) initiated with a Neutral at Sterne Agee... Midstates Petroleum (MPO) initiated with a Market Perform at Cowen... NASDAQ (NDAQ) initiated with a Hold at Deutsche Bank... Newfield Exploration (NFX) initiated with an Outperform at Iberia... Newpark Resources (NR) initiated with an Outperform at Credit Suisse... Nuverra Environmental (NES) initiated with a Buy at Stifel... Palo Alto (PANW) initiated with a Buy at Roth Capital... Petrobras (PBR) initiated with an Outperform at Cowen... RSP Permian (RSPP) initiated with a Hold at Deutsche Bank... Sensata (ST) initiated with an Equal Weight at Morgan Stanley... Stage Stores (SSI) initiated with a Neutral at Credit Suisse... Synergy Resources (SYRG) initiated with an Outperform at Cowen... TE Connectivity (TEL) initiated with an Overweight at Morgan Stanley... Twitter (TWTR) initiated with a Buy at Canaccord... Walter Investment (WAC) initiated with an Underweight at Barclays... Washington REIT (WRE) initiated with an Equalweight at Capital One... Yandex (YNDX) initiated with a Buy at Canaccord... Yara International (YARIY) initiated with a Neutral at Credit Suisse.
September 10, 2014
16:09 EDTEWEdwards Lifesciences initiated with a Buy at Sterne Agee
Subscribe for More Information
September 3, 2014
09:03 EDTEWNovation enters heart valve agreement with Edwards Lifesciences
Novation and Edwards Lifesciences announced they have entered into a three-year, sole-source strategic relationship that provides the world's market leading heart valve therapies to the more than 100,000 members and affiliates of VHA, UHC, Children's Hospital Association and Provista. The new agreement with Edwards for its heart valve product portfolio enables Novation to enter the heart valve category for the first time, and expands on the previous relationship between the companies for critical care technologies.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use